SSA
NMRA icon

Schonfeld Strategic Advisors’s Neumora Therapeutics NMRA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-521,013
Closed -$5.52M – 2406
2024
Q4 		$5.52M Buy
521,013
+381,676
+274% +$4.57M 0.03% 472
2024
Q3 		$1.84M Sell
139,337
-87,248
-39% -$1.02M 0.01% 916
2024
Q2 		$2.23M Sell
226,585
-22,010
-9% -$228K 0.01% 864
2024
Q1 		$3.42M Sell
248,595
-14,405
-5% -$233K 0.02% 783
2023
Q4 		$4.48M Buy
+263,000
New +$3.23M 0.03% 544

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Schonfeld Strategic Advisors's NMRA Position: Q1 2025 in Review

Schonfeld Strategic Advisors sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 521,013 shares — an estimated $5.52M sold.

Schonfeld Strategic Advisors first reported a position in NMRA in Q4 2023 and held it in 5 quarters. The position peaked at $5.52M in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Schonfeld Strategic Advisors reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 521,013 Neumora Therapeutics shares in Q1 2025, an estimated $5.52M.
  • Schonfeld Strategic Advisors first reported a position in Neumora Therapeutics in Q4 2023 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Neumora Therapeutics position peaked at $5.52M in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2025, filed 15 May 2025.